




Q1 2017 Results

May 25th, 2017

Presented by:

René Goehrum
Chairman, President, and CEO



This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.


By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

Sales, EBITDA and NIAT Quarter Ended March 31

Affected by:

- Excess wholesaler inventory y/e 2016
- Reduction in wholesaler inventory carrying levels YoY- Q1



- **Q1 2017 pharmaceutical sales of \$3.65 million increased 3% over Q1 2016**
 - FeraMAX[®] 150 Canadian sales volumes (units) decreased 8% Q1 2017 versus Q1 2016
 - Higher 2016 year-end wholesaler customer inventory levels
 - Wholesaler customer inventory levels approx. 1 week lower Mar. 31, 2017 vs. Mar. 31, 2016
 - Secondary sales by wholesalers to pharmacies increased 11% Q1 2017 versus Q1 2016
 - FeraMAX[®] Powder Canadian sales volumes (units) increased 4% Q1 2017 over Q1 2016
 - RepaGyn[®] sales volumes (units) increased 37% Q1 2017 over Q1 2016


Q1 2017 Sales Summary (continued)

- Cathejell® Jelly 2% sales volumes (units) increased 16% Q1 2017 over Q1 2016
- Aguettant System® PFS sales volumes (units) increased 228% Q1 2017 over Q1 2016
- Atropine PFS re-launched March 2016, Phenylephrine PFS launched November 2016
- FeraMAX® International sales (\$) increased 17% Q1 2017 over Q1 2016
- Based on existing customer orders, the majority of 2017 International sales expected in Q2 – Q4 2017
 - Tracking to deliver >50% sales growth vs. 2016

Pharmaceutical Sales By Quarter

Q1'17 vs. Q4 '16

- International Sales -40%
- Impact of trade inventory management



International FeraMAX Sales now recorded in 9 consecutive quarters

- **March 2017:** A 2nd Canadian hospital announces initiation of a Cysview® program
- **April 2017:** Company extends in-license agreement for Cathejell® to 2024

- Since its 2012 launch, Cathejell® has posted double-digit year-over-year sales growth

Cathejell®

2% lidocaine hydrochloride jelly, USP


- **May 2017:** FeraMAX® named #1 recommended iron supplement brand in Canada for second consecutive year

- EnsembleIQ Healthcare Group annual survey of 2,505 Canadian physicians and pharmacists
 - % of both physicians and pharmacists surveyed naming FeraMAX® #1 in 2017 increased from 2016 survey results





1. Canadian Key Opinion Leaders firmly support the use of Cysview®
2. Second hospital has announced the initiation of a Cysview® program
3. Recent published data indicates that Cysview® reduces the progression of bladder cancer
4. Canadian Pharmacoeconomic analysis shows Cysview® is cost effective
 - Accepted for two presentations: Canadian Urological Association conference (June '17)
 - Accepted for publication: Canadian Urological Association Journal (June '17)
5. Cysview® in Flexible Cystoscopy: Phase 3 study results presented at the AUA (May '17)
 - Improved detection of additional patients (21.5%) with bladder cancer in the surveillance setting
 - US to file with FDA for expanded use
 - BioSyent evaluating the impact of this data for Canadian market and filing with Health Canada



- **Long selling cycle**
- **Cysview® does not fit easily into existing hospital processes / channels**
 - Cysview® is approved as a drug but does not have a therapeutic effect
- **Key customers are surgeons**
 - Surgeons rarely use drugs
 - Lack familiarity / experience with hospital drug approval and implementation processes

Sales growth will be driven by organic growth in the Company's existing product portfolio as well as incremental growth from new products and new international markets:

Existing product portfolio growth drivers

- FeraMAX®
- FeraMAX® International – Sales to existing markets
- CYSVIEW®
- Cathejell® Jelly 2%
- RepaGyn®
- Aguetant System®

New products and new markets

- FeraMAX® International – Sales to new markets
- 2 Cardiovascular products; upon Health Canada approval
- Women's Health prescription drug product; upon Health Canada approval

New in-licensed products

- To be announced – active deal funnel

AS AT

ASSETS

	March 31, 2017	December 31, 2016	% Change
Trade receivables	\$ 1,809,851	\$ 1,924,949	-6%
Other receivables	68,316	16,228	321%
Inventory	1,737,027	1,560,050	11%
Prepaid expenses and deposits	339,145	269,704	26%
Derivative assets	50,294	32,025	57%
Short term investments	691,435	683,200	1%
Cash and cash equivalents	13,353,162	13,056,086	2%
Current Assets	18,049,230	17,542,242	3%
Equipment	286,208	291,331	-2%
Intangible assets	1,347,125	1,277,235	5%
Deferred tax asset	124,235	137,375	-10%
TOTAL NON CURRENT ASSETS	1,757,568	1,705,941	3%
TOTAL ASSETS	\$ 19,806,798	\$ 19,248,183	3%

LIABILITIES AND SHAREHOLDERS' EQUITY


Current liabilities	\$ 1,951,863	\$ 2,358,226	-17%
Deferred tax liability	136,267	163,241	-17%
Long term debt	-	-	0%
Total Equity	17,718,668	16,726,716	6%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 19,806,798	\$ 19,248,183	3%

Working Capital +6%
from Dec 31, 2016


Cash and ST
investments of
\$14,044,597
+2% from Dec. 31,
2016

Zero Debt

March 31 Cash and Q1 Cash Generation (“CG”)



Return on Equity (“ROE”)



Quarter	NIAT	Diluted EPS	
Q1 2017	\$ 901,556	\$ 0.06	\$0.29
Q4 2016	\$1,094,822	\$ 0.08	
Q3 2016	\$1,247,380	\$ 0.08	
Q2 2016	\$1,015,449	\$ 0.07	
Q1 2016	\$ 951,854	\$ 0.07	\$0.26
Q4 2015	\$ 762,602	\$ 0.05	
Q3 2015	\$1,188,536	\$ 0.08	
Q2 2015	\$ 851,039	\$ 0.06	

Fully diluted TTM EPS to Mar 31, 2017: \$0.29
+12% vs. TTM Mar 31, 2016 (\$0.26)



Stock Information

May 23, 2017

Exchange & Trading Symbol:
May 23, 2017 closing stock price (CAD)
52 Week Hi / Low:
Current Shares:
Warrants:
Options:
Fully Diluted:
P/E Ratio (TTM):
P/B Ratio:

TSXV: RX
\$8.14
\$9.12 / \$6.85
14,472,453
0
170,999
14,643,452
27.99
6.65

Thank you

www.BioSyent.com

www.sedar.com

www.tmxmoney.com

www.BioSyentPFS-System.ca

www.Cathejell.ca

www.CYSVIEW.ca

www.FeraMAX.com

www.Proktis-M.ca

www.RepaGyn.ca